– USA, CA – Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell therapies for autoimmune and inflammatory diseases, today announced the appointments of Katina Dorton and Dr. John Davis (M.D., MPH) to its Board of Directors.
“Katina has exceptional business acumen and financial expertise honed from an international career spanning investment banking and finance in biotechnology and life sciences. John is a highly-respected and accomplished leader in drug development and a rheumatologist with vast experience in industry and academia. He will provide critical expertise as we move our Treg therapies into the clinic to treat rheumatoid arthritis and other autoimmune diseases. We are pleased to welcome Katina and John to our board,” said Co-founder and CEO, Dr. Jeff Bluestone.
About Katina Dorton, J.D., MBA,
Katina Dorton is an experienced financial executive, corporate director, and CFO. She has served as CFO at multiple private and public biotechnology companies, including Nodthera, Inc., a company developing NLRP3 inhibitors for inflammatory diseases, Repare Therapeutics, Inc., AVROBIO, Inc., and Immatics GmbH, where she guided early adoptive cell therapies. Early in her career, Ms. Dorton served as a Managing Director in investment banking for Morgan Stanley and Needham & Company, and as an attorney at Sullivan & Cromwell. She currently sits on the boards of Fulcrum Therapeutics, Inc., and TScan Therapeutics, Inc., and previously served on the boards of directors of Pandion Therapeutics and US Ecology.
“Sonoma Bio has put the capabilities in place to truly shift the treatment paradigm of autoimmune and inflammatory diseases,” said Ms. Dorton. “I’m pleased to join the board and help guide the company through its continued growth and evolution.”
She earned her J.D. from the University of Virginia School of Law and an MBA from George Washington University.
About Dr. John Davis, M.D., MPH,
Dr. John Davis serves on the Board of Directors at Rheos Medicines and is a strategic advisor and member of the Scientific Advisory Boards at HIBio Therapeutics and Oak Hill Bio. He is also an attending volunteer physician at the Boston VA Medical Center Rheumatology Clinic and President of Norte Health Consulting. Dr. Davis has held numerous executive leadership roles at biopharmaceutical companies including Head of Research and Development/CMO at Magenta Therapeutics, SVP of Early Clinical Development at Pfizer, Global Head of Immunology, and VP at Baxalta and Therapeutic Area Head and Senior Group Director at Genentech. He was also a Professor of Clinical Medicine, Director of the Clinical Research Center, Lupus Clinic, and Spondylitis Clinic at UCSF.
“Sonoma Bio has a compelling approach to solving the autoimmunity puzzle, built on decades of research by pioneers in immune tolerance and Treg biology,” said Dr. Davis. “As a drug developer and rheumatologist, I am inspired by their mission to develop durable therapies that restore balance to the immune system for patients suffering from these diseases.”
Dr. Davis earned an M.D. and M.S. from the University of Maryland and holds an MPH in epidemiology from the University of California, Berkeley. He trained in Internal Medicine and Rheumatology/Autoimmune Disease at UCSF and NIH and is a Fellow in both the American College of Physicians and the American College of Rheumatology.
About Sonoma Biotherapeutics
Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted and durable Treg cell therapies designed to cure autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.
For more information visit sonomabio.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
